At the news
? BEARISHIMPACT 8/10 8-K filed Mar 3, 2026 at 07:08 ET
Karyopharm Therapeutics amended its credit agreement and entered into a forbearance agreement with its lenders and noteholders to defer principal and interest payments until September 2026, contingent on the company raising at least $25 million in equity financing by June 10, 2026. This restructuring indicates severe liquidity pressure and financial distress.
- Karyopharm entered into a Second Amendment to its Credit and Guaranty Agreement to defer principal and interest payments
- The deferral is contingent on the company raising $25 million in equity financing by June 10, 2026 (the 'Capital Raise Trigger')
- The company also entered into a Forbearance Agreement with 100% of its lenders and noteholders
- The forbearance covers payment defaults on convertible notes due 2028 and 2029
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access